Arcus Biosciences EPS - Earnings per Share 2017-2022 | RCUS

Arcus Biosciences eps - earnings per share from 2017 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Arcus Biosciences Annual EPS
2021 $0.71
2020 $-2.24
2019 $-1.93
2018 $-1.43
2017 $-29.03
2016 $-20.80
Arcus Biosciences Quarterly EPS
2022-03-31 $-0.96
2021-12-31 $3.99
2021-09-30 $-1.11
2021-06-30 $-1.09
2021-03-31 $-1.08
2020-12-31 $-0.71
2020-09-30 $0.03
2020-06-30 $-0.93
2020-03-31 $-0.63
2019-12-31 $-0.37
2019-09-30 $-0.51
2019-06-30 $-0.64
2019-03-31 $-0.41
2018-12-31 $0.51
2018-09-30 $-0.25
2018-06-30 $-0.32
2018-03-31 $-1.37
2017-12-31 $-6.57
2017-09-30 $-11.86
2017-06-30 $-5.64
2017-03-31 $-4.96
2016-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.368B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.299B 9.94
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.420B 16.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.085B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.716B 0.00
Emergent Biosolutions (EBS) United States $1.842B 7.89
Myovant Sciences (MYOV) United Kingdom $0.984B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.517B 0.00
Gelesis Holdings (GLS) United States $0.358B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.10
SQZ Biotechnologies (SQZ) United States $0.095B 0.00